FDA Official Foresees Reduced Biosimilar Data Burden
Deep Product Understanding Expected To Move Regulators To Reduce Clinical Data Requirements
Insulin biosimilars are one example where the FDA determined comparative clinical immunogenicity studies were not necessary • Source: Alamy 
